At 12 months, using a GnRH antagonist conferred an absolute risk reduction in major cardiovascular and cerebrovascular events by 18.1% (95% CI 4.6–31.3, p = 0.032); CVD in this study was defined as myocardial infarction (MI), cerebrovascular events, death, percutaneous angioplasty, or hospitalizations due to cardiac events. The gene discussed is GNRH1; the disease is myocardial infarction.